Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05142800 · ClinicalTrials.gov registry record
Screening For BCRL In Targeted Therapy For Breast Cancer
A clinical trial of Lymphedema and Breast Cancer Metastatic, sponsored by Massachusetts General Hospital.
- Active
- Registry status
- 166
- Enrollment target
- 1
- Study location
NCT05142800: Active study of Lymphedema and Breast Cancer Metastatic, sponsored by Massachusetts General Hospital.
NCT05142800 is a study of Lymphedema and Breast Cancer Metastatic that is active but no longer recruiting, run by Massachusetts General Hospital. The registered enrollment target is 166 participants, below the 9,295-participant average among 34 other Lymphedema trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05142800, a study of Lymphedema and Breast Cancer Metastatic, is active but no longer recruiting, sponsored by Massachusetts General Hospital.
- ACTIVE NOT RECRUITING
- Registry status
- 166 participants
- Enrollment target
- 1
- Study location
Study Summary
This a prospective, longitudinal study designed to track edema and Breast Cancer Related Lymphedema (BCRL) onset in breast cancer patients taking targeted therapy treatments for early and metastatic breast cancer. A Perometer and Sozo devise will be used to measure volume changes
Primary Outcome
Greater than or equal to 10% arm volume change from the first pre-treatment (targeted therapy) measurement, detected by perometry, occurring at least three months after breast surgery
Conditions Studied
Interventions
- DEVICE Perometer
- DEVICE SOZO device
Study Locations (1)
Massachusetts
- Massachusetts General Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 166 participants |
| Start Date | 2018-12-13 |
| Est. Completion | 2026-09-30 |
What the registry record for NCT05142800 still lists
NCT05142800 is an observational study that tracks outcomes without assigning an intervention. The registered 166 participants enrollment target is mid-sized for trials with a published cap, below the 9,295-participant average among 34 other Lymphedema trials with a reported enrollment target (98% lower).
The record links to 10 conditions, with Lymphedema appearing as the primary indexed condition, and to 2 interventions - of which Perometer is the first listed.
NCT05142800 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05142800 about?
NCT05142800 is a clinical study titled "Screening For BCRL In Targeted Therapy For Breast Cancer". This a prospective, longitudinal study designed to track edema and Breast Cancer Related Lymphedema (BCRL) onset in breast cancer patients taking targeted therapy treatments for early and metastatic breast cancer. A Perometer and Sozo devise will be used to measure volume changes
What is the current status of trial NCT05142800?
This trial is currently active not recruiting. The enrollment target is 166 participants. The study started on 2018-12-13. Estimated completion is 2026-09-30.
What conditions does trial NCT05142800 study?
This clinical trial studies the following conditions: Lymphedema, Breast Cancer Metastatic, Edema, Lymphedema Arm, Lymphedema of Upper Arm.
What interventions are being tested in trial NCT05142800?
The interventions under investigation include: Perometer (DEVICE), SOZO device (DEVICE).
Who is sponsoring clinical trial NCT05142800?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05142800 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphedema
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05142800's enrollment target sits among peer trials
166 14th of 34 higher than 21 of 34 other Lymphedema trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Lymphedema trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Lymphedema Surveillance Study
RECRUITING
-
Efficacy of GLP-1 Receptor Agonists in Treating Upper and Lower Extremity Lymphedema
RECRUITING · Early Phase 1
-
Reversing External-beam Radiotherapy-associated Fibrosis Syndrome: an Interventional Bayesian Adaptive Randomized-controlled Orphan Drug Platform Trial for Orodental Sequelae (Reverse-fibrose)
RECRUITING · Phase 2
-
A Real-World Registry of Chronic Wounds and Ulcers
RECRUITING
-
A Study of a Comprehensive Prevention Program to Reduce Lymphedema After Axillary Lymph Node Dissection in People With Breast Cancer
RECRUITING · Phase 3
-
Lymphedema Prevention Through Immediate Lymphatic Reconstruction (LILY) Trial.
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02747303 · 166 participants · Phase 2
Frameless Stereotactic Radiosurgery for Intact Brain Metastases
- NCT03806283 · 166 participants
Mechanisms of Pregnancy Vascular Adaptations
- NCT04040452 · 166 participants · Phase 4
Continuous vs Intermittent Ketorolac for Pain Control in Peds CV Surgery
- NCT04375813 · 166 participants · Phase 2
Trial of Encapsulated Rapamycin (eRapa) for Bladder Cancer Prevention
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI